10:48 AM EDT, 08/06/2025 (MT Newswires) -- Prothena ( PRTA ) shares were up more than 11% in recent Wednesday trading after the company highlighted Novo Nordisk's ( NVO ) Q2 earnings call announcement that it expects to advance coramitug into a phase 3 program in 2025.

Coramitug, initially developed by Prothena ( PRTA ) and acquired by Novo Nordisk ( NVO ) in 2021, is a potential first-in-class amyloid depleter antibody for ATTR amyloidosis with cardiomyopathy.

Prothena ( PRTA ) said it is eligible to receive a milestone payment once prespecified enrollment criteria are met in the phase 3 trial.

Under the terms of the deal with Novo Nordisk ( NVO ), Prothena ( PRTA ) said it is eligible to receive up to $1.2 billion upon achievement of clinical development and sales milestones, including $100 million earned to date.

Price: 7.83, Change: +0.80, Percent Change: +11.31